Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 4/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norlevorphanol SCHEMBL6900806 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL29851122 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL23822 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL4759025 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL13383458 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL18920299 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL20584891 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL21095579 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL20808855 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 | |
| Norlevorphanol SCHEMBL14743778 | 1.00 | SIGMAR1 (1.00) | SIGMAR1SLC22A1GRIN1GRIN2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6319 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-12036192-B2 | Combination treatments for opioid crisis | PRESTI MICHAEL (US) | 2024-07-16 | — | — | US | claimed |
| US-20240165022-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-05-23 | — | — | US | claimed |
| WO-1995014460-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 1995-06-01 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| EP-0290482-B1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | UNIV RUTGERS (US) | 1995-03-08 | — | — | EP | claimed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | claimed |
| US-4940586-A | Skin permeation enhancer compositions using sucrose esters | ALZA CORPORATION (US) | 1990-07-10 | — | — | US | claimed |
| US-4806341-A | BACKING LAYER, POLYMER MATRIX DISC WITH DRUG MICRODISPERSED THEREIN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1989-02-21 | — | — | US | claimed |
| US-4464378-A | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-08-07 | — | — | US | claimed |
| EP-0077393-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | The University of Kentucky Research Foundation (US) | 1983-04-27 | — | — | EP | claimed |
| WO-1982003768-A1 | NOVEL METHOD OF ADMINISTERING NARCOTIC ANTAGONISTS AND ANALGESICS AND NOVEL DOSAGE FORMS CONTAINING SAME | UNIV KENTUCKY (US) | 1982-11-11 | — | — | WO | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |